COMPANY PROFILE

Alzprotect

Explore full profile

Biopharmaceutical company which develop new bioactive molecules for the treatment of neurodegenerative diseases

Loos, FranceFounded 2007Biotech & Life Sciences

Valuation $50–100M Last recorded · 2018

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Alzprotect

Alzprotect is a biopharmaceutical company focused on the development of drug candidates aimed at treating neurodegenerative diseases such as Alzheimer's disease (AD) and tauopathies, including Progressive Supranuclear Palsy (PSP). The company operates in the healthcare and pharmaceutical market, targeting patients suffering from these debilitating conditions. Alzprotect's business model revolves around the discovery, development, and clinical trials of its drug candidates. Revenue is generated through the successful progression of these drugs through clinical trials, leading to potential partnerships, licensing agreements, and eventual commercialization. The company serves a critical need in the medical community by addressing diseases with significant unmet medical needs.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2007
Headquarters: Loos, France
Employees: 9
Open positions: None listed
Dealroom signal: 61.4/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Developer Tools, Biotechnology, Drug Development, Neurology, Alzheimers Disease, Molecular, Spinout, Biotech and Pharma, biotech medtech and e-health
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Jun 2022	$340K	—	Michael J. Fox Foundation for Parkinson's Research	↗
SERIES B✓Equity / VC	Jan 2018	$15M	$62M	Finovam · Xerys · Nord France Amorcage	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Margin	Margin
2026	—	—
2025	—	—
2024	—	—
2023	—	—
2022	—	—
2021	—	—
2020	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Alzprotect website traffic

Latest recorded traffic for Alzprotect is 1.2K monthly website visits, up 48.1% over the last three months. Alzprotect's team declined 25% over the past year.

Latest monthly visits1.2K 3-month web change+48.1% 1-year team growth-25%

Monthly website visitsMar 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational	57	$26M	$70M
STSeekyo TherapeuticsA privately-owned biotech company developing a Smart Chemotherapy, selective to tumours, safe for patients	Saint-Maur-des-Fossés, France	Operational
ANAntabioAntabio is a clinical-stage biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO	Labège, France	Operational
CECellectisDeveloping allogeneic CAR-T cells	Paris, France	Operational
GEGenfitDevelops drugs for the prevention and treatment of cardiometabolic and neurodegenerative diseases	Loos, France	Operational
PHPharnextDevelopment of treatments for severe neurological diseases	Paris, France	Closed
GBGenSight BiologicsDevelops innovative therapies for mitochondrial and neurodegenerative diseases	Paris, France	Operational
LTLys TherapeuticsInnovative biotherapies targeting neurological diseases with a focus on stroke and multiple sclerosis	Caen, France	Operational